Mizuho assumed overage of Cencora (COR) with an Outperform rating and $280 price target. The company remains well-positioned to generate both EBIT and EPS growth in FY25 at least in line with its long-term targets, despite potential for modest Rx and/or price erosion with its largest customer Walgreens (WBA), the analyst tells investors in a research note. Mizuho adds that it also sees minimal change in Cencora’s operating strategy from the CEO transition to Bob Mauch, as Mauch has been with the company for an extended period.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora price target raised to $245 from $240 at Jefferies
- Cencora, Inc. Navigates Complex Risks: Health Crises, Natural Disasters, and Geopolitical Challenges Threaten Stability
- Cencora files automatic mixed securities shelf
- Cencora Expands Specialty Healthcare with RCA Acquisition
- Cencora price target raised to $285 from $275 at UBS